Vaxcyte (PCVX) director Moncef Slaoui files Form 3 reporting zero share ownership

Q: Does Moncef Slaoui own any Vaxcyte (PCVX) shares according to this Form 3?

According to the Form 3, Moncef Slaoui reports no securities owned in Vaxcyte, with total shares beneficially owned following the reported position shown as 0 shares under direct ownership on the form.

Q: Are there any buy or sell transactions in this Vaxcyte (PCVX) Form 3?

The Form 3 includes no buy or sell transactions . It is an initial ownership report that simply states " No securities owned. " and shows total shares following the reported position as 0 for Moncef Slaoui.

Q: How is ownership type reported for Moncef Slaoui in the Vaxcyte (PCVX) Form 3?

The Form 3 identifies Moncef Slaoui’s ownership type as direct , with total shares following the reported position listed as 0 . This indicates he directly holds no Vaxcyte securities as of this initial ownership report.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Vaxcyte, Inc. director Moncef Slaoui filed an initial Form 3 as a reporting person and disclosed that he currently holds no securities of the company. The filing shows total beneficial ownership of 0 shares of Vaxcyte common stock following the reported position and lists no purchase or sale transactions.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Slaoui Moncef

Role null

Type	Security	Shares	Price	Value
holding	No securities owned.	--	--	--

Holdings After Transaction: No securities owned. — 0 shares (Direct, null)

Footnotes (1)

Key Figures

Total shares owned after filing: 0 shares

1 metrics

Total shares owned after filing 0 shares Total shares following reported position for Moncef Slaoui

Key Terms

Form 3, beneficial ownership, reporting person

3 terms

Form 3 regulatory

"Form 3 is the initial statement of beneficial ownership for insiders"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

beneficial ownership financial

"Form 3 is the initial statement of beneficial ownership for insiders"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

reporting person regulatory

"The Form 3 shows that director Moncef Slaoui is a reporting person"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Understanding Insider Trading Forms →

Available on EDGAR 06/23/2026 - 04:20 PM Accepted by SEC EDGAR 06/23/2026 - 04:20 PM

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Slaoui Moncef

(Last)

(First)

(Middle)

C/O VAXCYTE, INC.

825 INDUSTRIAL ROAD, SUITE 300

(Street)

SAN CARLOS

CALIFORNIA

94070

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
06/17/2026

3. Issuer Name and Ticker or Trading Symbol
Vaxcyte, Inc. [ PCVX ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
No securities owned.	0	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)

Explanation of Responses:

Remarks:

	Moncef Slaoui, by /s/ Peter N. Efremenko, Attorney-In-Fact	06/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What does the Vaxcyte (PCVX) Form 3 filing by Moncef Slaoui show?

The Form 3 shows that director Moncef Slaoui is a reporting person for Vaxcyte and currently reports no securities owned, with total beneficial ownership of 0 shares of company stock following the reported position.

Does Moncef Slaoui own any Vaxcyte (PCVX) shares according to this Form 3?

According to the Form 3, Moncef Slaoui reports no securities owned in Vaxcyte, with total shares beneficially owned following the reported position shown as 0 shares under direct ownership on the form.

Are there any buy or sell transactions in this Vaxcyte (PCVX) Form 3?

The Form 3 includes no buy or sell transactions. It is an initial ownership report that simply states "No securities owned." and shows total shares following the reported position as 0 for Moncef Slaoui.

What is the significance of a Form 3 filing for Vaxcyte (PCVX)?

Form 3 is the initial statement of beneficial ownership for insiders such as directors. This filing establishes Moncef Slaoui’s starting position in Vaxcyte, which is reported as 0 shares owned at the time of the report.

How is ownership type reported for Moncef Slaoui in the Vaxcyte (PCVX) Form 3?

The Form 3 identifies Moncef Slaoui’s ownership type as direct, with total shares following the reported position listed as 0. This indicates he directly holds no Vaxcyte securities as of this initial ownership report.